@EBoo80 It's fascinating isn't it? It makes me wonder whether there's similar variation for other medications. I never really got on with hormonal contraceptives, the impact on my mood was horrendous. Yet other people are fine.
I also wonder if because so many of us are taking this on private prescription and engaging on forums like this, whether we are taking more control of how we manage the doses and the impact. A friend of mine was prescribed Wegovy by her GP, and followed the path for increasing doses. I recently heard she'd stopped, because of the side effects. Maybe if she'd felt more in control of that herself she'd have titrated up more gradually, rather than blindly following her doctor's instructions. A busy overworked GP is understandably going to be following standard guidelines, not researching the ins and outs of microdosing.
I certainly imagine that if I had been part of an MJ clincial trial, with a set protocol and no flexibility I'd have dropped out of the trial as soon as there was the first dose increase to 5mg. It wold have been recorded as adverse side effects. There's no room in an ethically approved trial to start messing around with the doses.
This is more like citizen science where we are all contributing our own experiences to a body of data. It is interesting to see how that data is being used - for example some pharmacies offering more flexible options around maintenance, whereas the mainstream large clinical trials followed a standard path of increasing to 15mg and maintaining on that dose, even once a BMI of 25 had been achieved.
I watched a youtube video about microdosing on MJ. The presenter was describing the vast number of GLP 1 receptors across the body: panceas, brain and stomach being the key ones for the mechanism that results in appetite supression, satiety, and leads to weight loss. But there are also receptors in the kidneys, heart, blood vessels. I can only assume that there is a normal human variation in a) the number of receptors that individuals have; and b) the sensitivity of those receptors.